Safety ✅ Efficiency 😜7 Jun 2023 20:40
Avacta know what they are sitting on.
In early RNS’s to the market their only concern was safety, the language they used was prove safety and they have a blockbuster, No mention of Efficiency because they know if AVA6000 hits the tumour with no safety concerns then
Dox in the tumour will be Dox.
RNS 11/08/21 first patient dosed
“If the study shows that the pre|CISIONTM technology is effective in reducing systemic toxicity of Doxorubicin in humans, then that would open up an extensive and proprietary pipeline for Avacta of next-generation pre|CISIONTM pro-drug chemotherapies with significant clinical and commercial advantages in a chemotherapy market that is expected to exceed $74 billion by 2027.
RNS 29/11/21 FDA approval IND AVA6000
“Provided that the study shows that the pre|CISIONTM technology is effective in reducing systemic toxicity of Doxorubicin, then that would open up an extensive and proprietary pipeline for Avacta of next-generation pre|CISIONTM chemotherapies with significant clinical and commercial advantages in a chemotherapy market that is expected to exceed $74 billion by 2027”
RNS 03/02/22 first dose escalation.
AVA6000 has been designed to limit cell penetration of the drug, and therefore its cell killing effect, until it is specifically activated by fibroblast activation protein α (FAP) which is in high concentration in many solid tumours compared with healthy tissues.The resulting reduced exposure of healthy tissues to active doxorubicin has the potential to significantly increase its therapeutic index by reducing the incidence of adverse effects, including cardiotoxicity and myelosuppression.
GLA
Sign In
Follow the stocks
